Nelson Dusetti: The importance of molecular signatures in the personalization of treatments for PDAC

Nelson Dusetti shared on LinkedIn:

“We are pleased to announce the release of our article in The Francophone Journal HGOD, Hépato-Gastro and Oncologie Digestive addressing the importance of molecular signatures in the personalization of treatments for pancreatic ductal adenocarcinoma (PDAC).

The severity of this disease, combined with the limited available treatments and the variability in therapeutic responses, highlights the urgent need for treatment personalization. Recent research has identified molecular signatures based on transcriptomic analyses and chemotherapy sensitivity tests. Ongoing clinical trials are currently evaluating their effectiveness in guiding treatments for PDAC patients.

We invite you to read this article and follow our research to learn how these innovations could transform the management of this disease.”

Tissue and blood molecular markers

Authors: Jérôme Cros, Rémy Nicolle, Nelson Dusetti

Moreposts featuring Nelson Dusetti on oncodaily.com

Nelson Dusetti is a Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.